Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
暂无分享,去创建一个
P. Chevallier | M. Mohty | H. Avet-Loiseau | N. Ifrah | J. Delaunay | J. Harousseau | N. Milpied | A. Pigneux | M. Hunault | R. Garand | P. Turlure | T. Guillaume | S. Girault | N. Dmytruk